Efferon raises €4.3M to expand sepsis treatment technology into new markets

Efferon, a biotech company developing hemoadsorption devices designed to remove endotoxins and excessive inflammatory mediators from the bloodstream, has raised €4.3 million from existing private investors in the DACH region. Check out our earlier interview with Efferon CEO Dima Romashin. Originally developed for critical care settings such as sepsis and septic shock, Efferon’s technology is approved and used across Europe. More than 30,000 treatments have been performed using the company’s…